A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Sanoff HK, Deal AM, Patel J, Sorah JD, Gaddy J, O'Neil B, Turk A, Irvin W, Boles J, Lee MS, McRee A, Wardell AC, Weck KE, Basch E, Wood WA, Innocenti F.
Sanoff HK, et al. Among authors: lee ms.
Oncologist. 2024 Jun 5:oyae122. doi: 10.1093/oncolo/oyae122. Online ahead of print.
Oncologist. 2024.
PMID: 38837045